You are here

  • Home
  • Archive
  • Volume 77, Issue 5
  • Response to: ‘The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies’ by Tillet et al

Article info

Article menu
Download PDFPDF
Correspondence response
Response to: ‘The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies’ by Tillet et al

Authors

  • Sofia Ramiro Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands PubMed articlesGoogle scholar articles
  • Josef S Smolen Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria Department of Medicine, Hietzing Hospital, Vienna, Austria PubMed articlesGoogle scholar articles
  • Robert B M Landewé Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands Zuyderland Hospital, Heerlen, The Netherlands PubMed articlesGoogle scholar articles
  • Désirée van der Heijde Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands PubMed articlesGoogle scholar articles
  • Laure Gossec UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Sorbonne Universités, Paris, France Department of Rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sofia Ramiro, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, Leiden, The Netherlands; sofiaramiro{at}gmail.com
View Full Text

Citation

Ramiro S, Smolen JS, Landewé RBM, et al
Response to: ‘The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies’ by Tillet et al
Annals of the Rheumatic Diseases 2018;77:e24.

Publication history

  • Received July 10, 2017
  • Accepted July 18, 2017
  • First published August 16, 2017.
Online issue publication 
April 12, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.